Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators, enhancers |
Mechanism MC1R modulators(Melanocortin receptor 1 modulators), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma, Cutaneous Malignant | Phase 2 | United States | 01 Jun 2023 | |
| Metastatic melanoma | Phase 2 | United States | 01 Jun 2023 | |
| Unresectable Melanoma | Phase 2 | United States | 01 Jun 2023 | |
| Mucosal Melanoma | Phase 1 | United States | 05 Mar 2021 | |
| Uveal Melanoma | Phase 1 | United States | 05 Mar 2021 |





